Polyhydramnios and Oligohydramnios

No Results

No Results


The amniotic fluid that bathes the fetus is necessary for its proper growth and development. It cushions the fetus from physical trauma, permits fetal lung growth, and provides a barrier against infection. Normal amniotic fluid volume varies. The average volume increases with gestational age, peaking at 800-1000 mL, which coincides with 36-37 weeks’ gestation. An abnormally high level of amniotic fluid, polyhydramnios, alerts the clinician to possible fetal anomalies. An inadequate volume of amniotic fluid, oligohydramnios , results in poor development of the lung tissue and can lead to fetal death.

Polyhydramnios occurs in 1% of pregnancies, [1]  whereas oligohydramnios occurs in about 11% of pregnancies. [2]  No age variables are recognized.

In pregnancies affected by polyhydramnios, approximately 20% of neonates are born with a congenital anomaly of some type; therefore, the delivery of these newborns in a tertiary care setting is preferred. This article presents the causes, outcomes, and treatments of polyhydramnios and oligohydramnios, as well as their effects on the developing fetus and neonate.

Rupture of the membranes is the most common cause of oligohydramnios. However, because the amniotic fluid is primarily fetal urine in the latter half of the pregnancy, the absence of fetal urine production or a blockage in the fetus’s urinary tract can also result in oligohydramnios. Fetal swallowing, which occurs physiologically, reduces the amount of fluid, and an absence of swallowing or a blockage of the fetus’s gastrointestinal tract can lead to polyhydramnios.

A near term fetus produces 500-1200 mL of urine and swallows between 210 and 790 mL of amniotic fluid per day. [3]

The underlying cause of the excessive amniotic fluid volume is obvious in some clinical conditions and is not completely understood in others. Causes include the following:

In a study by Kollmann et al of 860 singleton pregnancies complicated by polyhydramnios, 68.8% of the polyhydramnios cases were idiopathic, whereas maternal diabetes was found in 19.8% of cases; congenital anomalies, in 8.5%; and a positive TORCH (toxoplasmosis, other [such as syphilis, varicella-zoster, parvovirus B19], rubella, cytomegalovirus, herpes infection) serology, in 2.9%. [4]

Causes of oligohydramnios include the following:

If polyhydramnios is not associated with any other findings, the prognosis is usually good. According Desmedt et al, there is a 61% perinatal mortality in polyhydramnios associated with a fetal or placental malformation. [6]  About 20% of infants with polyhydramnios have some type of an anomaly; in these cases, the prognosis depends on the severity of the anomaly. Yefet et al reported that even with normal detailed prenatal ultrasonographic evaluation, polyhydramnios (amniotic fluid index [AFI] >24 cm) is associated with an increased rate of fetal malformations, genetic syndromes, neurologic disorders, and developmental delay, conditions that may only be diagnosed postnatally. [1]

In a study of 163 women with idiopathic polyhydramnios, resolution was more likely when it was diagnosed early in pregnancy and when the AFI was low. [7] When idiopathic polyhydramnios persisted across the pregnancy, there was an increased risk of macrosomia and preterm delivery.

Studies show that as the severity of polyhydramnios increases, the likelihood of determining the etiology increases. In cases of mild polyhydramnios, the likelihood of finding a significant problem is only about 16.5%; this should be communicated to the parents. 

In the setting of oligohydramnios with renal agenesis, mortality is 100%. Milder forms of renal dysplasia or obstructive uropathy can be associated with a mild to severe degree of pulmonary hypoplasia and long-term renal failure. In cases of pulmonary hypoplasia, the effectiveness of many treatments such as the administration of surfactant, high-frequency ventilation, and nitric oxide has not been established. The prognosis in these cases is related to the volume of amniotic fluid and the gestational age at which oligohydramnios develops.

Borderline oligohydramnios (AFI 5.1-8 cm) does not appear to be a risk factor for adverse perinatal outcomes in uncomplicated, late preterm pregnancies. [8]

When Chamberlin used ultrasonography to evaluate the perinatal mortality rate (PMR) in 7562 patients with high-risk pregnancies, the PMR of patients with normal fluid volumes was 1.97 deaths per 1000 patients. [9]  However, the PMR increased to 4.12 deaths per 1000 patients with polyhydramnios and 56.5 deaths per 1000 patients with oligohydramnios.

In twin gestation with twin-to-twin transfusion, polyhydramnios may occur in the recipient twin, and oligohydramnios may occur in the donor. This complication is associated with high morbidity and mortality rates.


Idiopathic polyhydramnios appears to increase the risk of prolonged first stage of labour, nonvertex presentation, and cesarean delivery. [10] Preterm labor and delivery occurs in approximately 26% of mothers with polyhydramnios. Other complications include premature rupture of the membranes (PROM), abruptio placenta, malpresentation, and postpartum hemorrhage. [11]

Studies show an increased risk of associated fetal anomalies in more severe forms of polyhydramnios. In a series, 20% of cases of polyhydramnios involved associated fetal anomalies, including problems of the gastrointestinal system (40%), central nervous system (26%), cardiovascular system (22%), or genitourinary system (13%). [12]  Among these cases of polyhydramnios, multiple gestations occurred in 7.5%, 5% were due to maternal diabetes, and the remaining 8.5% were due to other causes. However, at least 50% of the patients had no associated risk factors.


The mortality rate in oligohydramnios is high. The lack of amniotic fluid allows compression of the fetal abdomen, which limits movement of its diaphragm. In addition to chest wall fixation, the lack of amniotic fluid flowing in and out of the fetal lung leads to pulmonary hypoplasia.

Oligohydramnios is also associated with meconium staining of the amniotic fluid, fetal heart conduction abnormalities, umbilical cord compression, poor tolerance of labor, lower Apgar scores, and fetal acidosis. In cases of intrauterine growth restriction (IUGR), the degree of oligohydramnios is often proportional to growth restriction, is frequently reflective of the extent of placental dysfunction, and is associated with a corresponding increase in the PMR.

Maternal body mass index (BMI) does not appear to be associated with oligohydramnios in late gestation. [13]  However, there is an increased risk of primary cesarean delivery with increasing maternal BMI.


Risks and complications of amnioinfusion include amniotic fluid embolism, maternal respiratory distress, increased maternal uterine tone, and transient fetal respiratory distress. An increase in the risk of maternal or fetal infection is not substantiated.

Risks of amniocentesis include fetal loss (1-2%). Other complications are placental abruption, preterm labor, fetal-maternal hemorrhage, maternal Rh sensitization, and fetal pneumothorax. The risk of fetal infection is slightly increased.


The primary complications of oligohydramnios are those related to fetal distress before or during labor. The risk of fetal infection is increased in the presence of prolonged rupture of the membranes.

Yefet E, Daniel-Spiegel E. Outcomes from polyhydramnios with normal ultrasound. Pediatrics. 2016 Feb. 137 (2):e20151948. [Medline].

Locatelli A, Zagarella A, Toso L, Assi F, Ghidini A, Biffi A. Serial assessment of amniotic fluid index in uncomplicated term pregnancies: prognostic value of amniotic fluid reduction. J Matern Fetal Neonatal Med. 2004 Apr. 15 (4):233-6. [Medline].

Hamza A, Herr D, Solomayer EF, Meyberg-Solomayer G. Polyhydramnios: causes, diagnosis and Therapy. Geburtshilfe Frauenheilkd. 2013 Dec. 73 (12):1241-6. [Medline]. [Full Text].

Kollmann M, Voetsch J, Koidl C, et al. Etiology and perinatal outcome of polyhydramnios. Ultraschall Med. 2014 Aug. 35 (4):350-6. [Medline].

Harper L, Waubant A, Vignes J, et al. Can quantity of amniotic fluid reliably predict postnatal renal function in boys with posterior urethral valves: a decision curve analysis. Prenat Diagn. 2017 Sep. 37 (9):931-4. [Medline].

Desmedt EJ, Henry OA, Beischer NA. Polyhydramnios and associated maternal and fetal complications in singleton pregnancies. Br J Obstet Gynaecol. 1990 Dec. 97 (12):1115-22. [Medline].

Odibo IN, Newville TM, Ounpraseuth ST, et al. Idiopathic polyhydramnios: persistence across gestation and impact on pregnancy outcomes. Eur J Obstet Gynecol Reprod Biol. 2016 Apr. 199:175-8. [Medline].

Sahin E, Madendag Y, Tayyar AT, et al. Perinatal outcomes in uncomplicated late preterm pregnancies with borderline oligohydramnios. J Matern Fetal Neonatal Med. 2017 Aug 16. 1-4. [Medline].

Chamberlain PF, Manning FA, Morrison I, Harman CR, Lange IR. Ultrasound evaluation of amniotic fluid volume. II. The relationship of increased amniotic fluid volume to perinatal outcome. Am J Obstet Gynecol. 1984 Oct 1. 150 (3):250-4. [Medline].

Zeino S, Carbillon L, Pharisien I, et al. Delivery outcomes of term pregnancy complicated by idiopathic polyhydramnios. J Gynecol Obstet Hum Reprod. 2017 Apr. 46 (4):349-54. [Medline].

Rosenberg VA, Buhimschi IA, Dulay AT, et al. Modulation of amniotic fluid activin-a and inhibin-a in women with preterm premature rupture of the membranes and infection-induced preterm birth. Am J Reprod Immunol. 2012 Feb. 67 (2):122-31. [Medline].

Ben-Chetrit A, Hochner-Celnikier D, Ron M, Yagel S. Hydramnios in the third trimester of pregnancy: a change in the distribution of accompanying fetal anomalies as a result of early ultrasonographic prenatal diagnosis. Am J Obstet Gynecol. 1990 May. 162 (5):1344-5. [Medline].

Blitz MJ, Rochelson B, Stork LB, et al. Maternal body mass index and amniotic fluid index in late gestation. J Ultrasound Med. 2017 Aug 29. [Medline].

Pri-Paz S, Khalek N, Fuchs KM, Simpson LL. Maximal amniotic fluid index as a prognostic factor in pregnancies complicated by polyhydramnios. Ultrasound Obstet Gynecol. 2012 Jun. 39 (6):648-53. [Medline].

Magann EF, Haas DM, Hill JB, Chauhan SP, Watson EM, Learman LA. Oligohydramnios, small for gestational age and pregnancy outcomes: an analysis using precise measures. Gynecol Obstet Invest. 2011. 72 (4):239-44. [Medline].

Odibo IN, Whittemore BS, Hughes DS, Simmons PM, Ounpraseuth ST, Magann EF. Addition of color Doppler sonography for detection of amniotic fluid disturbances and its implications on perinatal outcomes. J Ultrasound Med. 2017 Sep. 36 (9):1875-81. [Medline].

Abdel-Fattah SA, Carroll SG, Kyle PM, Soothill PW. Amnioreduction: how much to drain?. Fetal Diagn Ther. 1999 Sep-Oct. 14 (5):279-82. [Medline].

Patrelli TS, Gizzo S, Cosmi E, et al. Maternal hydration therapy improves the quantity of amniotic fluid and the pregnancy outcome in third-trimester isolated oligohydramnios: a controlled randomized institutional trial. J Ultrasound Med. 2012 Feb. 31 (2):239-44. [Medline].

Cabrol D, Jannet D, Pannier E. Treatment of symptomatic polyhydramnios with indomethacin. Eur J Obstet Gynecol Reprod Biol. 1996 May. 66 (1):11-5. [Medline].

Kramer WB, Van den Veyver IB, Kirshon B. Treatment of polyhydramnios with indomethacin. Clin Perinatol. 1994 Sep. 21 (3):615-30. [Medline].

Mamopoulos M, Assimakopoulos E, Reece EA, Andreou A, Zheng XZ, Mantalenakis S. Maternal indomethacin therapy in the treatment of polyhydramnios. Am J Obstet Gynecol. 1990 May. 162 (5):1225-9. [Medline].

Biggio JR Jr, Wenstrom KD, Dubard MB, Cliver SP. Hydramnios prediction of adverse perinatal outcome. Obstet Gynecol. 1999 Nov. 94 (5 pt 1):773-7. [Medline].

Brace RA, Resnik R. Dynamics and disorders of amniotic fluid. In: Creasy RK, Resnik R, eds. Maternal-Fetal Medicine. 4th ed. Philadelphia, PA: WB Saunders; 1999. 632-43.

Fanaroff AA, Martin RJ. Neonatal-Perinatal Medicine: Diseases of the Fetus and Infant. 6th ed. St Louis, MO: Mosby; 1997. 315-9.

Harrison MR, Golbus MS, Filly RA, eds. The Unborn Patient: Prenatal Diagnosis and Treatment. 2nd ed. Philadelphia, PA: WB Saunders; 1990. 139-49.

Hill LM, Breckle R, Thomas ML, Fries JK. Polyhydramnios: ultrasonically detected prevalence and neonatal outcome. Obstet Gynecol. 1987 Jan. 69 (1):21-5. [Medline].

Jones KL. Oligohydramnios sequence. In: Jones KL, ed. Smith’s Recognizable Patterns of Human Malformation. 5th ed. Philadelphia, PA: WB Saunders; 1997.

Kilpatrick SE. Histologic prognostication in soft tissue sarcomas: grading versus subtyping or both? A comprehensive review of the literature with proposed practical guidelines. Ann Diagn Pathol. 1999 Feb. 3 (1):48-61. [Medline].

Macri CJ, Schrimmer DB, Leung A, Greenspoon JS, Paul RH. Prophylactic amnioinfusion improves outcome of pregnancy complicated by thick meconium and oligohydramnios. Am J Obstet Gynecol. 1992 Jul. 167 (1):117-21. [Medline].

Morales WJ, Talley T. Premature rupture of membranes at Am J Obstet Gynecol</i>. 1993 Feb. 168 (2):503-7. [Medline].

Phelan JP, Ahn MO, Smith CV, Rutherford SE, Anderson E. Amniotic fluid index measurements during pregnancy. J Reprod Med. 1987 Aug. 32 (8):601-4. [Medline].

Pitt C, Sanchez-Ramos L, Kaunitz AM, Gaudier F. Prophylactic amnioinfusion for intrapartum oligohydramnios: a meta-analysis of randomized controlled trials. Obstet Gynecol. 2000 Nov. 96 (5 pt 2):861-6. [Medline].

Rib DM, Sherer DM, Woods JR Jr. Maternal and neonatal outcome associated with prolonged premature rupture of membranes below 26 weeks’ gestation. Am J Perinatol. 1993 Sep. 10 (5):369-73. [Medline].

Schumacher B, Moise KJ Jr. Fetal transfusion for red blood cell alloimmunization in pregnancy. Obstet Gynecol. 1996 Jul. 88 (1):137-50. [Medline].

Vergani P, Ghidini A, Locatelli A, et al. Risk factors for pulmonary hypoplasia in second-trimester premature rupture of membranes. Am J Obstet Gynecol. 1994 May. 170 (5 Pt 1):1359-64. [Medline].

Xiao ZH, Andre P, Lacaze-Masmonteil T, Audibert F, Zupan V, Dehan M. Outcome of premature infants delivered after prolonged premature rupture of membranes before 25 weeks of gestation. Eur J Obstet Gynecol Reprod Biol. 2000 May. 90 (1):67-71. [Medline].

Hidaka N, Sato Y, Kido S, Fujita Y, Kato K. Expectant management of pregnancies complicated by fetal growth restriction without any evidence of placental dysfunction at term: Comparison with routine labor induction. J Obstet Gynaecol Res. 2017 Sep 11. [Medline].

Brian S Carter, MD, FAAP Professor of Pediatrics, University of Missouri-Kansas City School of Medicine; Attending Physician, Division of Neonatology, Children’s Mercy Hospital and Clinics; Faculty, Children’s Mercy Bioethics Center

Brian S Carter, MD, FAAP is a member of the following medical societies: Alpha Omega Alpha, American Academy of Hospice and Palliative Medicine, American Academy of Pediatrics, American Pediatric Society, American Society for Bioethics and Humanities, American Society of Law, Medicine & Ethics, Society for Pediatric Research, National Hospice and Palliative Care Organization

Disclosure: Nothing to disclose.

Roland L Boyd, DO Neonatologist, Section of Neonatology, Neonatal Services, Ltd

Roland L Boyd, DO is a member of the following medical societies: American Academy of Osteopathy, American Academy of Pediatrics, American College of Osteopathic Pediatricians

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

David A Clark, MD Professor and Martha Lepow Chairman of Pediatrics, Professor of Obstetrics and Gynecology, Albany Medical College; Director, Children’s Hospital at Albany Medical Center

David A Clark, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American College of Nutrition, American Forestry Association, American Pediatric Society, Capital District Pediatric Society, Christian Medical and Dental Associations, European Society for Paediatric Research, Eastern Society for Pediatric Research, Floyd W Denny Pediatric Alumni Society, Medical Society of the State of New York, New York Academy of Sciences, Society for Pediatric Research

Disclosure: Nothing to disclose.

Dharmendra J Nimavat, MD, FAAP Associate Professor of Clinical Pediatrics, Department of Pediatrics, Division of Neonatology, Southern Illinois University School of Medicine; Staff Neonatologist, Clinical Director, NICU Regional Perinatal Center, HSHS St John’s Children’s Hospital

Dharmendra J Nimavat, MD, FAAP is a member of the following medical societies: American Academy of Pediatrics, American Association of Physicians of Indian Origin

Disclosure: Nothing to disclose.

Ted Rosenkrantz, MD Professor, Departments of Pediatrics and Obstetrics/Gynecology, Division of Neonatal-Perinatal Medicine, University of Connecticut School of Medicine

Ted Rosenkrantz, MD is a member of the following medical societies: American Academy of Pediatrics, American Pediatric Society, Eastern Society for Pediatric Research, American Medical Association, Connecticut State Medical Society, Society for Pediatric Research

Disclosure: Nothing to disclose.

Polyhydramnios and Oligohydramnios

Research & References of Polyhydramnios and Oligohydramnios|A&C Accounting And Tax Services